Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease

Top Cited Papers
Open Access
Abstract
Background—Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the ARISTOTLE trial included a substantial number of patients with valvular heart disease and only excluded patients with clinically significant mitral stenosis or mechanical prosthetic heart valves.